

CITATION REPORT

List of articles citing

Prognostic and predictive value of PDL1 expression in breast cancer

DOI: 10.18632/oncotarget.3216
Oncotarget, 2015, 6, 5449-64.

Source: <https://exaly.com/paper-pdf/60887016/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
380	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. 2015 , 10, 189		56
379	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015 , 6, 13506-19	3.3	87
378	High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. <i>Oncotarget</i> , 2015 , 6, 33972-81	3.3	123
377	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. 2015 , 26, 1488-93		179
376	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. 2015 , 7, 641-52		38
375	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. 2015 , 36, 822-846		191
374	Natural and therapy-induced immunosurveillance in breast cancer. 2015 , 21, 1128-38		196
373	Endocrine resistance in breast cancer--An overview and update. 2015 , 418 Pt 3, 220-34		200
372	Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development. 2015 , 7, 151-160		
371	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 495-508	4.4	40
370	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. <i>Oncotarget</i> , 2016 , 7, 33498-511	3.3	70
369	Immune checkpoints in aggressive breast cancer subtypes. 2016 , 63, 768-73		10
368	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. 2016 , 35, e40-54		25
367	PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. 2016 , 7, 784-93		100
366	Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. 2016 , 19, 242-251		45
365	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. 2016 , 17,		25
364	Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. 2016 , 11, e0156323		35

363	The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer. 2016 , 11, e0166680		34
362	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. 2016 , 11, e0167397		4
361	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETS. 2016 , 7, 484-9		81
360	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. <i>Oncotarget</i> , 2016 , 7, 74350-74361	3-3	31
359	CTC immune escape mediated by PD-L1. 2016 , 93, 138-9		25
358	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. 2016 , 5, e1196310		116
357	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. 2016 , 55, 626-39		63
356	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. 2016 , 5, 805		44
355	Immunotherapy for breast cancer: past, present, and future. 2016 , 35, 525-546		27
354	Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. 2016 , 14, 227		47
353	Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance. 2016 , 144, 539-562		7
352	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. <i>Human Pathology</i> , 2016 , 54, 17-24	3-7	100
351	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. 2016 , 13, 674-690		1246
350	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. 2016 , 46, 9-19		60
349	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 117-31	4-4	17
348	Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. 2016 , 146, 496-502		66
347	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. 2016 , 15, 55		151
346	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. 2016 , 8, 360-74		33

345	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. 2016 , 11, 753-761		45
344	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. <i>Scientific Reports</i> , 2016 , 6, 28910	4.9	116
343	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. 2016 , 10, 31-9		88
342	Triple-negative breast cancer [The past, present and future: recent and emerging trends in immunotherapy. <i>Breast Cancer Management</i> , 2016 , 5, 1-5	0.7	1
341	Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. 2016 , 21, 946-952		33
340	Checkpoint Inhibitors and Their Application in Breast Cancer. 2016 , 11, 108-15		33
339	Monocyte and interferon based therapy for the treatment of ovarian cancer. 2016 , 29, 109-15		15
338	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 2105-10	12.9	90
337	The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. 2016 , 5, e1085148		33
336	Prognostic significance of PD-L1 and PD-L2 in breast cancer. <i>Human Pathology</i> , 2016 , 47, 78-84	3.7	154
335	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. 2016 , 5, e1061176		19
334	Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. 2016 , 12, 421-30		13
333	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. 2017 , 24, 3-15		107
332	PD-L1, Galectin-9 and CD8 tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. 2017 , 6, e1273309		93
331	Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. 2017 , 108, 81-90		35
330	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. 2017 , 30, 577-586		88
329	Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. 2017 , 23, 436-443		35
328	[Androgen receptors in breast cancer: Expression, value and therapeutic prospects]. 2017 , 104, 363-369		3

327	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. 2017 , 6, e1278100		54
326	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. 2017 , 70, 255-259		71
325	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. 2017 , 141, 851-861		64
324	Emerging therapies for breast cancer. 2017 , 10, 98		37
323	Immunotherapy for the treatment of breast cancer. 2017 , 17, 797-812		10
322	Advances in systemic therapy for metastatic breast cancer: future perspectives. 2017 , 34, 119		26
321	Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. 2017 , 70, 860-867		30
320	PD-1/PD-L1 Pathway in Breast Cancer. 2017 , 40, 294-297		60
319	PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. 2017 , 140, 1384-1395		26
318	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. <i>Clinical Cancer Research</i> , 2017 , 23, 3371-3384	12.9	53
317	PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 19-30	4.4	70
316	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. 2017 , 49, 141-155		68
315	Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. 2017 , 8, e3004		61
314	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. 2017 , 5, 871-884		41
313	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. <i>Scientific Reports</i> , 2017 , 7, 11671	4.9	43
312	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. 2017 , 30, 1551-1560		30
311	Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues. 2017 , 99, 1129-1136		15
310	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. 2017 , 2, e000150		73

309	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. 2017 , 19, 64		71
308	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <i>Human Pathology</i> , 2017 , 66, 13-33	3-7	34
307	Biomarkers of response to PD-1/PD-L1 inhibition. 2017 , 116, 116-124		185
306	PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. 2017 , 35, 69-77		18
305	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. 2017 , 1026, 59-104		32
304	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.. 2017 , 1, 1-12		5
303	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 1141563-114162		172
302	New Immunotherapy Strategies in Breast Cancer. 2017 , 14,		54
301	Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. 2017 , 18,		45
300	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. 2017 , 8, 1412		54
299	Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. 2017 , 8, 1544		38
298	Risk Factors and Preventions of Breast Cancer. 2017 , 13, 1387-1397		389
297	Type II phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF- κ B. <i>Oncotarget</i> , 2017 , 8, 42414-42427	3-3	17
296	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. 2017 , 17, 690		27
295	PD-L1 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017 , 8, 51641-51651	3-3	29
294	Managing Expectations in the Transition to Proof of Concept Studies. 2017 , 12, 111-123		1
293	Mechanism of immune evasion in breast cancer. 2017 , 10, 1561-1573		46
292	PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. <i>Oncotarget</i> , 2017 , 8, 99901-99912	3-3	55

291	Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 99372-99381	3.3	14
290	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. 2018 , 105, 263-274		10
289	PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. 2018 , 19, 373-380		36
288	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. 2018 , 13, 16-21		52
287	Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer. 2018 , 41, 1049-1057		10
286	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. 2018 , 149, 253-261		17
285	Checkpoint Blockade. 2018 , 37-53		
284	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. 2018 , 78, 205-215		89
283	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. 2018 , 20, 815-826		43
282	The Basics of Cancer Immunotherapy. 2018 ,		2
281	Immunotherapy for Other Malignancies. 2018 , 125-142		
280	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. 2018 , 7, e1356144		77
279	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. 2018 , 500, 621-625		34
278	[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. 2018 , 51, 97-109		4
277	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. 2018 , 31, 1226-1236		40
276	An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. 2018 , 26, 611-619		16
275	Possible roles for glucocorticoid signalling in breast cancer. 2018 , 466, 38-50		22
274	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. 2018 , 24, 701-716		13

273	Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. 2017 , 7, e1376155	23
272	Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. 2018 , 18, e237-e244	25
271	PD-L1. 2018 , 71, 189-194	129
270	Breast cancer genomics and immuno-oncological markers to guide immune therapies. 2018 , 52, 178-188	68
269	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. 2018 , 1869, 78-84	82
268	Harnessing the immune system in the battle against breast cancer. 2018 , 7, 212520	14
267	Programmed Death 1 (PD1)-Mediated T-Cell Apoptosis and Cancer Immunotherapy. 2018 , 695-722	0
266	Correlation between tumor microenvironment-associated factors and the efficacy and prognosis of neoadjuvant therapy for rectal cancer. 2019 , 17, 1062-1070	12
265	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. 2018 , 2018, 2937012	25
264	The clinical promise of immunotherapy in triple-negative breast cancer. 2018 , 10, 6823-6833	81
263	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. 2018 , 13, 769-777	6
262	Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. 2018 , 16, 5214-5222	8
261	ER α is a negative regulator of PD-L1 gene transcription in breast cancer. 2018 , 505, 157-161	23
260	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. 2018 , 9, 1050	31
259	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. 2018 , 379, 2108-2121	1871
258	PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. 2018 , 24, 911-919	37
257	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival. 2018 , 7, e1509820	51
256	JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. 2018 , 18, e1205-e1215	33

255	The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 273-282	4.4	40
254	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661		133
253	Real-Time Tracking of -Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers. 2018 , 9, 825		15
252	Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. 2018 , 19,		29
251	Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. 2018 , 25, 2852-2857		7
250	Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. 2018 , 24, 379-390.e6		77
249	ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation. 2018 , 24, 630-641		53
248	Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. 2018 , 18, 4		57
247	CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. 2018 , 6, 54		26
246	A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. 2019 , 17, 131-139		50
245	Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. 2019 , 19, 673-679		17
244	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. 2019 , 20, 1231-1243		132
243	Expression of PD-L1 in primary breast carcinoma and lymph node metastases. 2019 , 2,		8
242	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	99
241	Advances in Targeted Therapies for Triple-Negative Breast Cancer. 2019 , 79, 1217-1230		45
240	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 1083-1091 ^{2.8}		11
239	PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	5
238	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. 2019 , 12, 111		45

237	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. 2019 , 5, 39		7
236	Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	4
235	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019 , 24, e1055-e1069	5.7	23
234	The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. 2019 , 1872, 188311		15
233	expression is associated with longer postoperative, survival in adrenocortical carcinoma. 2019 , 8, e1655362		16
232	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. 2019 , 7, 254		8
231	The Use of Immunotherapy to Treat Metastatic Breast Cancer. 2019 , 26, 941-962		9
230	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function. 2019 , 7, 257-268		51
229	simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. 2019 , 6, 190366		26
228	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019 , 11,	6.6	10
227	The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas. 2019 , 24, 1419-1428		6
226	The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. 2019 , 40, 143-151		21
225	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. 2019 , 15, 1951-1961		33
224	Immunotherapy in breast cancer: Current status and future directions. 2019 , 143, 295-349		24
223	The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast. 2019 , 152, 169-176		6
222	Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?. 2019 , 8,		5
221	Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog. 2019 , 2019, 9078209		8
220	Site-Specific Immuno-PET Tracer to Image PD-L1. 2019 , 16, 2028-2036		24

219	Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1043-1053	4.9	27
218	Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. 2019 , 20, 941-947		8
217	Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. <i>Cancers</i> , 2019 , 11,	6.6	21
216	Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. 2019 , 21, 28		42
215	PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. 2019 , 11, 353-357		2
214	Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. 2019 , 98, e15201		14
213	Breast Cancer. 2019 , 157-167		
212	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. 2019 , 14, 53-59		8
211	Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. 2019 , 68, 283-296		25
210	PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 571-584	4.4	32
209	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. 2019 , 19, 29-42		8
208	CD16NKG2A Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes. 2019 , 7, 208-218		19
207	An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. 2020 , 26, 511-526		24
206	PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. 2020 , 20, e99-e111		4
205	Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model. 2020 , 108, 115-125		10
204	Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?. 2020 , 26, 739-742		8
203	Triple negative breast cancer: A thorough review of biomarkers. 2020 , 145, 102855		71
202	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. 2020 , 476, 569-576		10

201	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. 2020 , 122, 94-101		13
200	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. 2020 , 122, 245-257		9
199	Triple-negative breast cancer-Role of immunology: A systemic review. 2020 , 26, 995-999		21
198	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. 2020 , 21, 44-59		422
197	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2019 , 12,	6.6	27
196	Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8 T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 582863	5.3	9
195	Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. 2020 , 12, 9375-9387		11
194	Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway. 2020 , 11, 2026		33
193	. 2020 ,		
192	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. 2020 , 11, 3584		41
191	Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. 2020 , 26, 2733-2745		5
190	Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis. 2020 , 11, 3086-3098		0
189	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	24
188	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 575978	5.3	2
187	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis.. 2020 , 9, 3804-3818		3
186	A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer. 2020 , 43, 573-583		0
185	The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. 2020 , 40, 4829-4841		7
184	Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. 2020 , 11, 4861		18

183	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020 , 12,	6.6	5
182	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. 2020 , 5, 141		13
181	Genomic Strategies for Personalized Cancer Therapy. 2020 , 1-60		
180	Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype. <i>Frontiers in Oncology</i> , 2020 , 10, 580345	5.3	4
179	Co-localization of CD169 macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. 2020 , 9, 1848067		2
178	CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. 2020 , 9, 1747688		5
177	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. <i>Clinical Cancer Research</i> , 2020 , 26, 1141-1151	12.9	24
176	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. 2020 , 15, 208-216		2
175	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. 2020 , 122, 1496-1506		15
174	Advances in targeted therapy for malignant lymphoma. 2020 , 5, 15		26
173	Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. 2020 , 40, 1487-1494		10
172	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020 , 12,	6.6	30
171	Expression of the immune checkpoint VISTA in breast cancer. 2020 , 69, 1437-1446		18
170	Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. <i>Cancers</i> , 2020 , 12,	6.6	19
169	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. 2020 , 34, 639-647		9
168	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. 2020 , 21,		23
167	Early stage triple negative breast cancer: Management and future directions. 2020 , 47, 201-208		5
166	Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. 2020 , 14, 951-963		9

165	XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2019 , 9, 1459	5.3	22
164	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. 2020 , 133, 853-862		6
163	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. 2020 , 9, 66		2
162	Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. 2021 , 72, 114-122		9
161	Pembrolizumab and atezolizumab in triple-negative breast cancer. 2021 , 70, 607-617		31
160	Metabolism and immunity in breast cancer. 2021 , 15, 178-207		5
159	Updates on the treatment of invasive breast cancer: Quo Vadimus?. 2021 , 145, 64-72		3
158	Triple-negative breast cancer: promising prognostic biomarkers currently in development. 2021 , 21, 135-148		16
157	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. 2021 , 2021, 6668573		3
156	Emerging role of circulating tumor cells in immunotherapy. 2021 , 11, 8057-8075		5
155	Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas. 2021 , 11,		5
154	MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors. 2021 , 45, 701-707		4
153	Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment. 2021 , 22,		16
152	A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling. 2020 , 11, 616188		0
151	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. 2021 , 12,		4
150	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	6
149	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. 2021 , 9,		4
148	Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. <i>Frontiers in Oncology</i> , 2021 , 11, 640690	5.3	3

147	Overview of recent advances in metastatic triple negative breast cancer. 2021 , 12, 164-182		9
146	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. 2021 , 895, 173867		11
145	Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer. 2021 , 21, 239		13
144	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.		0
143	The interplay of interleukin-17A and breast cancer tumor microenvironment as a novel immunotherapeutic approach to increase tumor immunogenicity. 2021 , 226, 152068		1
142	Immune checkpoint inhibitors in the treatment of cancer. 2021 ,		7
141	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 387-395	4.4	4
140	Predictive value of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer patients treated with neoadjuvant chemotherapy. 2021 ,		
139	Inpatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. 2021 , 29, 667-673		1
138	Triple-negative breast cancer: A run-through of features, classification and current therapies. 2021 , 22, 512		10
137	Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis. 2021 , 108, 622-631		7
136	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 409-424	4.5	4
135	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. <i>Cancers</i> , 2021 , 13,	6.6	5
134	The Immunology of Hormone Receptor Positive Breast Cancer. 2021 , 12, 674192		13
133	Trials of Immunotherapy in Triple Negative Breast Cancer. 2021 , 13, 171-185		1
132	Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
131	Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer. 2021 , 22, 2069-2077		0
130	Oleupin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. 2021 , 277, 119353		3

129	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. <i>Scientific Reports</i> , 2021 , 11, 14426	4.9	4
128	Immunotherapy: New insights in breast cancer treatment. 2021 , 29, 193-202		0
127	Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. <i>Cancers</i> , 2021 , 13,	6.6	7
126	Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug. 2021 , 135, 543-555		2
125	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. 2021 , 32, 983-993		35
124	Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells. 2021 , 22,		1
123	Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. 2021 , 154, 11-20		6
122	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing.		7
121	Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review. 2021 , 15, 533		
120	Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. 2021 , 19, 264		4
119	Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?. 2021 , 226, 153606		1
118	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. 2021 , 10, 1929724		4
117	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. 2021 , 15, 1178223421995854		
116	Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. 2020 , 27, 519-526		3
115	A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. 2017 , 124, 403-410		22
114	Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. 2018 , 38, 131-138		1
113	Innovations in targeted therapies for triple negative breast cancer. 2021 , 33, 34-47		3
112	Cancer biomarker profiling using nanozyme containing iron oxide loaded with gold particles. 2020 , 17, 20200180		6

111	PD-L1 Status in Refractory Lymphomas. 2016 , 11, e0166266		37
110	Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. 2020 , 15, e0240982		5
109	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. 2019 , 26, R157-R179		21
108	The NF-KB pathway and endocrine therapy resistance in breast cancer. 2019 , 26, R369-R380		40
107	Prognostic value of PDL1 expression in pancreatic cancer. <i>Oncotarget</i> , 2016 , 7, 71198-71210	3-3	59
106	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016 , 7, 76604-76612	3-3	77
105	Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. <i>Oncotarget</i> , 2017 , 8, 7614-7624	3-3	24
104	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 15584-15592	3-3	76
103	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <i>Oncotarget</i> , 2017 , 8, 54722-54734	3-3	30
102	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 66178-66194	3-3	42
101	Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. <i>Oncotarget</i> , 2017 , 8, 72755-72772	3-3	34
100	Prognostic value of PD -L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , 2018 , 9, 5058-5072	3-3	35
99	The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. <i>Oncotarget</i> , 2018 , 9, 6201-6212	3-3	29
98	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. <i>Oncotarget</i> , 2018 , 9, 13920-13933	3-3	36
97	POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2019 , 10, 1572-1588	3-3	13
96	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutic drugs may finally work through immune response. <i>Oncotarget</i> , 2016 , 7, 29794-29803	3-3	35
95	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. 2019 , 5,		5
94	Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. 2019 , 20, 2951-2957		4

93	Cancers du sein triple-négatifs : données actuelles et perspectives d'avenir. 2019 , 21, 33-39			1
92	MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. 2020 , 20, 317			3
91	Immunotherapy in breast cancer. 2019 , 18, 2			36
90	Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. 2019 , 51, 649-663			32
89	Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. <i>The Journal of Breast Health</i> , 2019 , 15, 235-241	1.5		10
88	The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. 2021 , 38, 147			1
87	Immunotherapy in Breast Cancer. 2019 , 541-552			
86	Actualidades en el manejo sistémico del cáncer de mama. 2020 , 10, 71-82			
85	Lymph nodes may be a source for immunotherapy in gastric cancer. <i>Oncotarget</i> , 2020 , 11, 1729-1736	3.3		1
84	The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. 2021 , 340, 168-187			4
83	[The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia]. 2020 , 82, 5-12			
82	PD-L1 expression is associated with higher residual cancer burden in triple-negative breast cancers with residual disease after neoadjuvant chemotherapy.			
81	Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis. 2020 , 99, e23359			0
80	Phenotypic functional activities of monocyte change during crosstalk with breast cancer cell and enhancing effect of metformin of IFN- γ -associated antitumor cytokine production.			
79	PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.. <i>The Journal of Breast Health</i> , 2022 , 18, 21-29	1.5		2
78	VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes. <i>Cancers</i> , 2021 , 13,	6.6		0
77	Multiplexed immunofluorescence identifies high stromal CD68PD-L1 macrophages as a predictor of improved survival in triple negative breast cancer. <i>Scientific Reports</i> , 2021 , 11, 21608	4.9		3
76	Triple-negative breast cancer [The past, present and future: recent and emerging trends in immunotherapy. <i>Breast Cancer Management</i> ,	0.7		

75	Advances in Molecular and Immunohistochemical Detection of Prognostic and Therapeutic Markers in Breast Cancer.		0
74	Therapeutic targeting of immune checkpoints with small molecule inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 529-541	3	8
73	Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study. <i>Breast Cancer: Targets and Therapy</i> , 2021 , 13, 603-615	3.9	
72	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
71	LncRNA KRT19P3 Is Involved in Breast Cancer Cell Proliferation, Migration and Invasion.. <i>Frontiers in Oncology</i> , 2021 , 11, 799082	5.3	2
70	A review of prognostic and predictive biomarkers in breast cancer.. <i>Clinical and Experimental Medicine</i> , 2022 , 1	4.9	3
69	Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.. <i>Oncologist</i> , 2022 , 27, e313-e327	5.7	2
68	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. <i>Molecular Diagnosis and Therapy</i> , 2022 , 1	4.5	
67	Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	0
66	HLA Class II Histocompatibility Antigen α Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.. <i>Cancers</i> , 2021 , 13,	6.6	0
65	PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.. <i>International Journal of Immunopathology and Pharmacology</i> , 2022 , 36, 39463320221078433		
64	Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	1
63	PDL1 positivity rate between triple negative and non-luminal Her2+ cases. <i>Current Cancer Therapy Reviews</i> , 2022 , 18,	0.4	
62	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 ,	4.9	0
61	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results.. <i>Cancers</i> , 2021 , 13,	6.6	0
60	PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. <i>Current Oncology</i> , 2022 , 29, 2895-2908	2.8	0
59	Image_1.jpg. 2018 ,		
58	Image_2.jpg. 2018 ,		

57 Image_3.jpeg. **2018,**

56 Table_1.XLSX. **2020,**

55 Table_2.XLSX. **2020,**

54 Table_3.XLSX. **2020,**

53 Table_4.XLSX. **2020,**

52 Table_5.XLSX. **2020,**

51 Table_6.XLSX. **2020,**

50 Table_7.XLSX. **2020,**

49 Table_8.XLSX. **2020,**

48 Table_1.DOCX. **2020,**

47 Novel biomarkers in triple-negative breast cancer - role and perspective. **2022,** 29-60

46 Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.. *Cancers*, **2022,** 14, 6.6 ○

45 PD-L1 expression in Congolese women with triplenegative breast cancer. *Journal of Cancer Prevention & Current Research*, **2022,** 13, 61-63 1.3

44 Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.. *Breast Cancer: Targets and Therapy*, **2022,** 14, 113-123 3.9 2

43 A Dual-Mode Imaging Nanoparticle Probe Targeting PD-L1 for Triple-Negative Breast Cancer. *Contrast Media and Molecular Imaging*, **2022,** 2022, 1-8 3.2

42 PD-L1 (SP142 and 22C3) Immunohistochemistry in Clinical Metastatic Triple Negative or Low Hormone Receptor Breast Carcinomas: Experience from a Large Academic Institution. *Human Pathology*, **2022,** 3.7 ○

41 Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. *Frontiers in Molecular Biosciences*, 9, 5.6

40 Recent progress in antibody-based therapeutics for triple-negative breast cancer. *Expert Opinion on Drug Delivery*, 8 ○

39	Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer. <i>Japanese Journal of Clinical Oncology</i> ,	2.8	
38	Tumor Microenvironment Characterization in Breast Cancer and an Immune Cell Infiltration Score Development, Validation, and Application. <i>Frontiers in Oncology</i> , 12,	5.3	
37	CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. <i>Cancers</i> , 2022 , 14, 3356	6.6	0
36	De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial. <i>Clinical Cancer Research</i> ,	12.9	1
35	Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome. <i>Clinical and Experimental Medicine</i> ,	4.9	0
34	Immunotherapy and breast cancer: an overview. <i>Current Opinion in Oncology</i> , Publish Ahead of Print,	4.2	2
33	Circulating proteins as predictive and prognostic biomarkers in breast cancer. <i>Clinical Proteomics</i> , 2022 , 19,	5	6
32	An Overview of Breast Cancer Therapy. 2022 , 242-258		
31	Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. <i>Immunotherapy</i> , 2022 , 14, 957-983	3.8	1
30	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. 2022 , 1-20		
29	Marker assessments in ER positive breast cancers - old markers, new applications?.		0
28	Fate decisions of breast cancer stem cells in cancer progression. 12,		
27	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. 9,		
26	Multiplex immunohistochemistry and high-throughput image analysis for evaluation of spatial tumor immune cell markers in human breast cancer. 2022 , 1-14		1
25	PD-L1 Expression in Triple-negative Breast Cancer – Comparative Study of 3 Different Antibodies. Publish Ahead of Print,		0
24	PD-L1 Expression in Breast Cancer Brain Metastases.		0
23	PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment – Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters. 2022 , 11, 5524		1
22	Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis. 1-11		0

21	Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. 2022 , 14, 4279	0
20	Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. 2022 , 22,	1
19	Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma.	0
18	Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining. 1-8	0
17	Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research 1-20	0
16	Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study. 2022 , 12, 2007	0
15	<i>P. gingivalis</i> infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T cell responses, and aggravates oral cancer.	0
14	Primary squamous cell carcinoma of the breast: A case report and review of the literature. 12,	0
13	PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. 2023 , 15, 447	0
12	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.	1
11	Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. 2023 , 86,	0
10	Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images. 2023 , 7,	0
9	<i>Dictyostelium</i> Differentiation-inducing Factor Derivatives Reduce the Glycosylation of PD-L1 in MDA-MB-231 Human Breast Cancer Cells. 2023 ,	0
8	Tailoring Treatment for Patients with Inflammatory Breast Cancer.	0
7	Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. 2023 , 24, 2969	0
6	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. 2023 , 13,	0
5	Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. 2023 , 24, 5730	0
4	Hereditary Breast Cancer Non-CDH1 Associated. 2023 , 361-386	0

- 3 The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress. **2023**, 124, 477-494
- 2 Crosstalk between triple negative breast cancer and microenvironment. **2023**, 14, 284-293
- 1 Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance. **2023**, 19, 81